CERBA-HEALTHCARE/CIRION
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230907759314/en/
CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosimilars/Biologics development including PKPD and Immunogenicity testing, it offers central lab full solutions with fast start-up capabilities for managing international multi-center clinical studies and supports specimen management for complex development projects. The company has a workforce of over 80 employees comprised of PhD holders, medical specialists and a network of renowned university researchers.
Cerba HealthCare appreciates CIRION’s reputation for its deep expertise with Large Molecules development and, high-quality services being fully GLP compliant, with an impressive client base including some of the world’s top 10 global pharmaceutical companies. Being CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accredited assures that their lab is scientifically endorsed to regulatory standards in the North American market.
CIRION offers a full range of services, from the development of specialized assays to laboratory testing required for clinical studies, allowing the company to meet the complex needs of their reputable clients. Furthermore, the company provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.
Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical and IVD trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in white-glove logistics solutions for immuno-oncology, anti-infectives, cell & gene therapies and metabolic disorders. Over the years, Cerba Research has evolved to become the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for global complex clinical research programs.
CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific. CIRION’s full-service offering will fit perfectly into Cerba Research’s multispecialty services portfolio and complement it. By combining deep expertise and agility of a specialist laboratory with the capacity, breadth and global reach of a central lab, Cerba Research is expanding its one-stop-shop offering for its clients.
Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically. It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect. Their extensive knowledge and unrivalled reputation will naturally make CIRION the Cerba Research center of excellence in bioanalytics across the globe, helping us accelerate fulfill our clients’ needs in the development of personalized medicine. We are proud to welcome CIRION’s renowned high-quality scientists and very much looking forward to onboarding the team.”
Dr. Sylvain Desrochers and Dr. Lise Dallaire, founders of CIRION added: “We are very proud of what CIRION has accomplished over the past 30 years, and yet, it was time to find a new foundation to bring our scientific contribution to the next level. It is an honor to join the Cerba HealthCare galaxy though their world class clinical research provider: with Cerba Research, we found the perfect breeding ground where our combined expertise and capabilities will help our teams meet the ever-changing scientific, logistical and analytical challenges of clinical studies. This is truly galvanizing stage for our people to see their purpose pursued at a greater scale and we will remain closely associated to the business operations of this new entity. The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 15 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
About Cerba Research
We offer world-class clinical research that helps life science companies to successfully develop the predictive and precision medicines of the future.
We combine the deep expertise and agility of the specialist laboratory with the capacity, breadth and global reach of a central lab. Our unique approach to patient data offers our customers the opportunity to have one partner for all their test services, with regular access and consistent support across all clinical trial phases.
Our customer centric approach means flexible solutions to unique challenges, providing reassurance and efficacy, whilst offering agility at scale. Our customers today are our partners tomorrow.
For more information visit www.cerbaresearch.com
About CIRION
CIRION is a leading contract research laboratory providing global central laboratory services for clinical studies and bioanalytical services highly specialized in Biologics/Biosimilars. It offers a comprehensive selection of PKPD/Immunogenicity methods’ development and validation, project management and clinical testing services (GLP and non GLP).
Based in the Montreal metropolitan area, a strategic hub for the management of multinational clinical trials, CIRION is well positioned to respond efficiently to international project requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907759314/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celonis Named a Leader in Process Intelligence Software12.8.2025 18:18:00 CEST | Press release
Celonis, a global leader in Process Mining, today announced it has been named a Leader in The Forrester Wave™: Process Intelligence Software, Q3 2025. According to the report, “Celonis is best suited to clients looking for a sophisticated platform that supports enterprise-wide process intelligence and control to transform operations.” Forrester also cited Celonis’ trailblazing role in the category, noting its early adoption of graph databases, an additional object-centric view of process performance, and an extended marketplace of partner-built solutions. “We are honored to be named a Leader in The Forrester Wave: Process Intelligence. This recognition is only possible because of the dedication and commitment of our customers, partners and Celonauts,” said Carsten Thoma, President and Board Director, Celonis. “Enterprise AI is set to reinvent operations. To deliver on its full potential, AI needs to understand how each business runs and how to make it run better. Our Process Intelligen
Empowering Developers to Monetize Anywhere: Xsolla Expands Platform Support for Cross-Platform Direct-to-Consumer Commerce12.8.2025 18:00:00 CEST | Press release
Unified Commerce Tools Now Available for Windows Stores, Epic Games Store, Discord, Pley, and the Web, Unlocking More Revenue Opportunities for Game Developers Xsolla, a global commerce company helping developers launch, grow, and monetize their games, announces today a major expansion of its platform support capabilities, reinforcing its position as the premier provider of cross-platform monetization solutions for developers. With the latest SDKs for Windows Stores and the Epic Games Store, a new strategic partnership with Pley, and the launch of the Xsolla Discord Bot, developers can now implement secure, streamlined commerce across PC, mobile, web, and community platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812673202/en/ (Graphic: Xsolla) Key Platform Expansions Now Available to Developers:SDK for Windows stores PC developers can access flexible monetization tools via Xsolla SDK for Windows Stores, offering
Gogo Galileo HDX Connectivity Option Now Available on Cessna Citation CJ4 Gen312.8.2025 15:00:00 CEST | Press release
Customers who will be taking delivery of the Cessna Citation CJ4 Gen3 business jet now have the option to include the Gogo Galileo HDX connectivity solution installed on their aircraft. By integrating Gogo Galileo HDX, customers can benefit from an additional global connectivity solution that delivers exceptional performance. Announced in October 2024, the CJ4 Gen3 is expected to enter into service in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812553974/en/ Gogo Galileo HDX connectivity option now available on Cessna Citation CJ4 Gen3 (Photo Credit: Textron Aviation). The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “Cessna Citation business jets are known for their luxury and productivity,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Whether for work or entertainment, this robust solution ensures customers’ in-flight exp
Unity Game Developers Can Now Enable Direct-to-Consumer Monetization With Xsolla’s New SDK12.8.2025 15:00:00 CEST | Press release
New Xsolla SDK for Unity Empowers Developers to Sell and Scale Games with Full Control of Their Revenue Xsolla, a global commerce company helping developers launch, grow, and monetize their games, today announces the launch of an SDK for Unity that expands monetization capabilities for developers using the Unity engine. This new SDK is a part of Xsolla’s continued mission to unlock direct-to-consumer revenue opportunities across all platforms - mobile, PC, and the web - without complex backend work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812923531/en/ (Graphic: Xsolla) Whether building a mobile-first title, a PC game, or a browser-based game, Unity developers can now integrate payments, enable in-game purchases, and create custom storefronts without relying on closed platforms. With a fast time-to-market, developers can start selling directly to their players and retain more of their revenue from day one, while ma
Pacific Avenue Capital Partners, a Leading Middle Market Private Equity Firm, Announces the Closing of More Than $1.65 Billion in Committed Capital12.8.2025 14:30:00 CEST | Press release
Pacific Avenue Capital Partners (“Pacific Avenue”), a leading global private equity firm focused on corporate carve-outs and other complex situations in the middle market, today announced the closing of its second fund, Pacific Avenue Fund II, with more than $1.65 billion in committed capital. This includes a €100+ million sidecar vehicle that will be used alongside Fund II to pursue European opportunities. Fund II and the European sidecar were each raised in a single closing and completed in less than four months. The vehicles were significantly oversubscribed and received strong support from both new and existing investors. “We are incredibly grateful for the strong support and confidence shown by our existing and new investors,” said Chris Sznewajs, Founder and Managing Partner of Pacific Avenue. “The overwhelmingly strong demand for Fund II and the European sidecar is a clear validation of our strategy.” Pacific Avenue strives to be the premier global partner for corporate carve-ou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom